CytRx Corporation (CYTR)
- Business Wire
CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients
CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that NantKwest, Inc. (NASDAQ: NK) ("NantKwest") and ImmunityBio, Inc. ("ImmunityBio") have announced that their ongoing Phase 2 clinical trials of a novel combination immunotherapy – which include CytRx’s licensed drug aldoxorubicin – for locally advanced or metastatic pancreatic cancer have produced early indications of increased survival rates for patients with no other approved treatment options. Interim results of the three-cohort trials, known as QUILT 88, show median survival rates more than doubled that of the historic rate in patients with advanced metastatic pancreatic cancer (for which no other FDA approved treatment exists).
- Business Wire
CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today provided an update on the U.S. Food and Drug Administration’s ("FDA") review of Orphazyme A/S’s (NASDAQ: ORPH) ("Orphazyme") New Drug Application ("NDA") for arimoclomol to treat Niemann-Pick Disease Type C ("NPC"). According to Orphazyme, the FDA has extended the review period with a standard extension of three months in order to complete the NDA review. The updated Prescription Drug User Fee Act ("PDUFA") target action date is June 17, 2021.
- Business Wire
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated ImmunityBio, Inc. ("ImmunityBio") and NantKwest, Inc. (NASDAQ: NK) ("NantKwest") on their proposed merger and announced plans to create a leading immunotherapy and cell therapy company.
